Tumor Cells for Oncology Research and Drug Development

Viable cell tumor bank for in vivo and ex vivo oncology research and drug development

products.png

Gain Access to the World’s Largest Bank of Viable Cryopreserved Tumor Cells

The bank contains over 100,000 tumor cells, covering more than 25 tissue types and 76 clinical diagnoses. Each of the specimens contains viable tumor cells that were cryofrozen as single cell suspensions for culture.

  • World’s largest collection of viable tumor cells
  • Many prior treated cells
  • Tested in vitro against common oncology drugs
  • Viable cells with potential to be grown

The bank has been collected over the past 20 years from a US population, with matched histology/pathology review and associated ex vivo treatment data for each specimen. View list of tumor types.

Additionally, each specimen has matching DNA, RNA, and protein available for screening targets of interest in order to identify particular tumor cases for subsequent studies, including ex vivo and in vivo drug screens.

Indications

Our tumor bank contains tumors from virtually all known common and rare cancer indications. Major cancer types such as breast, lung, colon, and ovarian average >10,000 specimens per indication. Less common cancers are also prominently featured, including small cell lung cancer and neuroendocrine tumors, for example. View list of tumor types.

Each specimen has been profiled against a panel of drugs ex vivo, and levels of resistance recorded; we leverage the drug resistance data to select tumor cells of interest for our partners’ drug treatment studies and molecular biomarker discovery. View list of drugs screened per indication.

These tumors are ideal for:

  • Ex vivo treatment studies
  • In vivo xenograft studies
  • Predictive biomarker discovery/development
  • Frequency/prevalence screens for target
  • Target identification

Representative Overview of Available Tumors

Bladder Lung (non-small cell) Ovarian
Brain Lung (small cell) Pancreas
Breast Lymphoid Prostate
Cervix Lymphoma Renal
Colon Mesothelioma Sarcoma
Endocrine Myeloma Skin
GI Nervous System Squamous carcinoma
Head & Neck Neuroendocrine Testicular
Leukemia Oral Uterus
Liver Other  

Tumor Specimens by Clinical Diagnosis

Acute lymphocytic leukemia
Acute non-lymphocytic leukemia
Adrenal carcinoma
Anemia, pancytopenia
Appendiceal carcinoma
Basal cell carcinoma
Benign
Bladder carcinoma
Brain tumor
Breast carcinoma
Carcinoid tumor
Cervical carcinoma
Choriocarcinoma
Chronic lymphocytic leukemia
Chronic myelogenous leukemia
CNS tumor
Colon carcinoma
Desmoplastic small round cell
Endometrial carcinoma
Esophageal carcinoma
Ewing’s sarcoma
Fallopian tube carcinoma
Gallbladder carcinoma
Gastrointestinal stromal tumor
Granulosa cell tumor
Hairy cell leukemia
Hodgkin’s lymphoma
Kidney carcinoma
Liver carcinoma
Lymphoproliferative disorder
Malignant fibrous histiocytoma
Malignant melanoma
Malignant mesothelioma
Merkel cell carcinoma
Miscellaneous tumor
Mixed mullerian tumor
Multiple myeloma
Myelodysplastic syndromes
Neuroblastoma
Neuroendocrine tumor
Non-Hodgkin’s lymphoma
Non-small cell lung cancer
Osteosarcoma
Ovarian (small-cell)
Ovarian carcinoma
Ovarian germ cell tumor
Ovarian LMP
Ovarian sarcoma
Pancreatic carcinoma
Parotid gland carcinoma
Peritoneal carcinoma
Primitive neuroectodermal
Prostate carcinoma
Pseudomyxoma peritonei
R/O malignant lymphoma
Salivary gland carcinoma
Sarcoma
Small cell carcinoma
Small intestine carcinoma
Squamous carcinoma of cervix
Squamous carcinoma of H&N
Squamous cell carcinoma
Squamous cell carcinoma, UPS
Squamous cell vulva
Stomach carcinoma
Testicular germ cell tumor
Thymoma
Thyroid carcinoma
Transitional cell kidney
Uterine sarcoma
Vaginal carcinoma
Waldenstrom macroglobulinemia
Wilm’s tumor

Drug Panels by Indication

Almost all of the cells in the collection were treated in vitro using a broad range of standard of care drugs to test drug sensitivity. This table outlines the list of drugs that the cells may have been tested against.

ANLL
1. Daunorubicin
2. Cytarabine
3. Mitoxantrone
4. Idarubicin
5. Carboplatin
6. Etoposide
7. Fludarabine
8. Topotecan

Sarcoma
1. Doxorubicin
2. Ifosfamide
3. Temozolomide
4. Cisplatin
5. Taxotere®
6. Gemcitabine
7. Topotecan

Multiple Myeloma
1. Melphalan
2. Vincristine
3. Doxorubicin
4. Dexamethasone
5. Cyclophosphamide
6. Carmustine
7. Etoposide
8. Alpha-Interferon

Lung (Non-Small Cell)
1. Carboplatin
2. Taxol®
3. Navelbine®
4. Etoposide
5. Gemcitabine
6. Topotecan
7. Cisplatin
8. Taxotere

Colorectal
1. 5-FU + Leucovorin
2. Irinotecan
3. 5-FU + Irinotecan
4. Oxaliplatin
5. Topotecan
6. Capecitabine
7. Floxuridine

Squamous
1. Cisplatin
2. Ifosfmide
3. Etoposide
4. Fluorouracil
5. Cyclophosphamide
6. Doxorubicin
7. Taxol

Renal Cell
1. Interleukin 2
2. Alpha-Interferon
3. Fluorouracil
4. Gemcitabine
5. Doxil®
6. Vinblastine
7. Interferon + Vinblastine
8. Mitomycin C

Endometrial
1. Cisplatin
2. Taxol
3. Doxorubicin
4. Ifosfamide
5. Etoposide
6. Cyclophosphamide
7. Topotecan

Ovarian
1. Carboplatin
2. Taxol
3. Topotecan
4. Doxil
5. Etoposide
6. Gemcitabine
7. Taxotere
8. Cisplatin
9. Cisplatin + Gemcitabine
10. Cyclophosphamide

Breast
1. Doxorubicin
2. Cyclophosphamide
3. Taxol
4. Fluorouracil
5. Navelbine
6. Taxotere
7. Gemcitabine
8. Cisplatin

Non-Hodgkin’s Lymphoma
1. Cyclophosphamide
2. Doxorubicin
3. Vincristine
4. Dexamethasone
5. Etoposide
6. Bleomycin
7. Cytarabine

Stomach/Gastric
1. Fluorouracil
2. Mitomycin C
3. Doxorubicin
4. Cisplatin
5. Etoposide
6. Gemcitabine
7. Taxol

Melanoma
1. Cisplatin
2. Temozolomide
3. Vinblastine
4. Taxotere
5. Navelbine
6. Gemcitabine
7. Navelbine + Taxotere
8. Alpha-Interferon

CLL
1. Fludarabine
2. Cyclophosphamide
3. Dexamethasone
4. Doxorubicin
5. Vincristine
6. Melphalan
7. Cladribine

Other Primary Site
1. Cisplatin
2. Doxorubicin
3. Fluorouracil
4. Cyclophosphamide
5. Taxol
6. Topotecan
7. Etoposide

Ask a Question / Request a Quote

Complete the form below to receive additional information about tumor cells for oncology research and drug development, or call:

+1 855 827 6968
6am - 5pm (PST)